SCHEMBL7209955

SCHEMBL7209955

NOC1(C(=O)O)CNCCC1S(=O)(=O)c1ccc(-c2cccc(Cl)c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.35
MMP13 P45452 2/20 0.35
CHRM1 P11229 8/20 0.35
CHRM3 P20309 4/20 0.35
PGR P06401 1/20 0.34
ACLY P53396 1/20 0.34
RORC P51449 1/20 0.34
BCL2L1 Q07817 1/20 0.34
MCL1 Q07820 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
SLC6A3 Q01959 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP7 P09237 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
MMP14 P50281 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyamine SCHEMBL7209949 0.84 MMP13 (0.42) KAT6AMMP13CHRM1CHRM3PGR
SCHEMBL7209957 0.82 MMP13 (0.41) MMP13CHRM1CHRM3PGRRORC
SCHEMBL7290264 0.77 MMP13 (0.55) MMP13CHRM1CHRM3RORCMMP1
SCHEMBL7290273 0.69 MGLL (0.41) KAT6AMMP13ACLYRORCSLC6A3
SCHEMBL7201008 0.66 MMP13 (0.54) MMP13MMP1MMP2MMP3MMP7
SCHEMBL7201763 0.65 MMP13 (0.55) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7199642 0.65 MMP13 (0.57) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7204063 0.65 MMP13 (0.53) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7202562 0.65 MMP13 (0.55) MMP13MMP1MMP2MMP3MMP7
SCHEMBL7205953 0.65 MMP13 (0.71) MMP13MMP1MMP2MMP3MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 KAT6A 127/4885MMP13 4/4885CHRM1 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.